1 Several lines of evidence suggest a crucial involvement of glutamate in the mechanism of action of anxiolytic and/or antidepressant drugs. The involvement of group I mGlu receptors in anxiety and depression has also been proposed. Given the recent discovery of a selective and brain penetrable mGlu5 receptor antagonists, the eect of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), i.e. the most potent compound described, was evaluated in established models of anxiety and depression. 2 Experiments were performed on male Wistar rats or male Albino Swiss or C57BL/6J mice. The anxiolytic-like eects of MPEP was tested in the con¯ict drinking test and the elevated plus-maze test in rats as well as in the four-plate test in mice. The antidepressant-like eect was estimated using the tail suspension test in mice and the behavioural despair test in rats. 3 MPEP (1 ± 30 mg kg 71) induced anxiolytic-like eects in the con¯ict drinking test and the elevated plus-maze test in rats as well as in the four-plate test in mice. MPEP had no eect on locomotor activity or motor coordination. MPEP (1 ± 20 mg kg 71) did shorten the immobility time in a tail suspension test in mice, however it was inactive in the behavioural despair test in rats. 4 These data suggest that selective mGlu5 receptor antagonists may play a role in the therapy of anxiety and/or depression, further studies are required to identify the sites and the mechanism of action of MPEP.

No abstract

No abstract